Keyphrases
18F-fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET)
33%
90th Percentile
9%
Abnormal Blood Pressure
13%
Age-matched
13%
Biomarker Model
33%
Blood Biomarkers
33%
Blood Pressure
6%
Body Mass Index
6%
Breast Cancer Mortality
16%
Breast Cancer Prevention
11%
Breast Cancer Risk
33%
Calibration Plot
9%
Cancer Radiotherapy
33%
Case-control Sample
6%
Confidence Interval
23%
Digital Biomarkers
33%
First Visit
6%
Hazard Ratio
11%
Head-and-neck Cancer
33%
Hemoglobin
13%
Hypertension
13%
Inflammation
6%
Late Xerostomia
33%
Logistic Regression
6%
Metabolic Dysregulation
13%
Metformin
33%
Metformin Use
11%
Midlife Women
33%
Moderate to Severe
9%
Nested Case-control Study
33%
New-onset Hypertension
33%
Normal Blood Pressure
13%
Obesity
6%
Obesity Body Mass Index
6%
Odds Ratio
6%
Parotid Gland Dose
9%
PET Image
33%
Platelet Count
6%
Platelets
6%
Red Blood Cell Count
6%
Risk Factors
11%
Risk Stratification
6%
Standardized Uptake Value
9%
Statin Use
33%
Statins
22%
Triglycerides
6%
Type 2 Diabetes Mellitus (T2DM)
33%
Validation Cohort
23%
White Blood Cells
6%
Xerostomia
19%
Medicine and Dentistry
Base
11%
Biological Marker
33%
Blood Glucose
33%
Blood Pressure
33%
Breast Cancer
66%
Breast Tumor
5%
Cancer Diagnosis
12%
Cancer Radiotherapy
33%
Cancer Risk
33%
Cancer Staging
11%
Carcinoma in Situ
5%
Contralateral
8%
Epidermal Growth Factor Receptor
5%
Estrogen Receptor
5%
Fluorodeoxyglucose F 18
33%
Gamma Urogastrone
5%
Hazard Ratio
22%
Head and Neck Cancer
33%
High Density Lipoprotein Cholesterol
14%
Low Density Lipoprotein Cholesterol
7%
Lymph Node
16%
Maturity Onset Diabetes of the Young
66%
Meta-Analysis
33%
Neoplasm
33%
Odds Ratio
11%
Parotid Gland
8%
Positron Emission Tomography
33%
Progesterone Receptor
5%
Random Effects Model
5%
Standardized Uptake Value
5%
Systematic Review
33%
Xerostomia
33%
Pharmacology, Toxicology and Pharmaceutical Science
Abnormal Blood Pressure
33%
Biological Marker
33%
Breast Cancer
100%
Breast Tumor
5%
Cancer Incidence
13%
Cancer Staging
11%
Carcinoma in Situ
5%
Case-Control Study
33%
Epidermal Growth Factor Receptor
5%
Estrogen Receptor
5%
Gamma Urogastrone
5%
High Density Lipoprotein Cholesterol
14%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
16%
Inflammation
16%
Low Density Lipoprotein Cholesterol
7%
Metformin
33%
Neoplasm
33%
Non Insulin Dependent Diabetes Mellitus
100%
Prevalence
16%
Progesterone Receptor
5%
Random Effects Model
5%
Statin (Protein)
33%
Triacylglycerol
20%
